It's important to Teva that COPAXONE® patients find affordable access to therapy. Teva’s Shared Solutions® helps patients find personalized financial solutions to help them start on 3-times-a-week COPAXONE® 40 mg/mL.
*Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply. See Terms and Conditions.
Teva’s Shared Solutions® has a team of dedicated Case Managers who research and understand your patients' insurance coverage and benefits, so you can be confident that someone is working hard to help make their COPAXONE® therapy affordable.
See the range of services offered by Teva’s Shared Solutions® Case Managers
For your patients who want to receive Teva’s COPAXONE®, you should also encourage them to take an active role in requesting Teva’s COPAXONE® with their pharmacy.
Specify Dispense as Written (DAW) to help ensure the pharmacy cannot substitute COPAXONE® without your authorization.
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of
The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.
While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.